admin – Page 4332 – Get News Story

Psoriasis Pipeline 2024: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Johnson and Johnson, Janssen Biotech, Leo Pharma, Merck, Novartis, Pfizer, AbbVie Inc

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Psoriasis pipeline constitutes 80+ key companies continuously working towards developing 80+ Psoriasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Psoriasis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Psoriasis Market.

The Psoriasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Psoriasis Pipeline Report:

Companies across the globe are diligently working toward developing novel Psoriasis treatment therapies with a considerable amount of success over the years.
Psoriasis companies working in the treatment market are Fresh Tracks Therapeutics, Inmagene, SFA Therapeutics, Palobiofarma, Sun Pharmaceutical Industries Limited, Biohaven Pharmaceuticals, Inc., Dr. Reddy’s, MetrioPharm, Celltrion, Amgen, Can-Fite Biopharma, and others, are developing therapies for the Psoriasis treatment

Emerging Psoriasis therapies in the different phases of clinical trials are- FRTX-03, IMG-008, SFA 002, PBF-1650, SCD-044, Rimegepant, PPC-06, MP1032, CT-P43, ABP 654, Piclidenoson, and others are expected to have a significant impact on the Psoriasis market in the coming years.
In December 2024, Bristol Myers Squibb (NYSE: BMY) announced that the POETYK PsA-1 and POETYK PsA-2 trials achieved significant secondary endpoints in PsA disease activity at Week 16. The safety profile of Sotyktu through 16 weeks of treatment in both the POETYK PsA-1 and POETYK PsA-2 trials was in line with the previously established safety profile observed in a Phase 2 PsA clinical trial and Phase 3 trials for moderate-to-severe plaque psoriasis.
In May 2024, InnoCare Pharma announced that it has completed subject enrollment for the Phase II clinical trial of ICP-488, a treatment aimed at individuals with moderate to severe plaque psoriasis. This achievement represents a significant milestone in the drug’s development, as it is a tyrosine kinase 2 (TYK2) JH2 allosteric inhibitor. The randomized, multi-center, double-blind, placebo-controlled trial seeks to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of ICP-488 in adult patients in China.
In May 2024, Zai Lab administered the first dose to a participant in a Phase II clinical trial of ZL-1102, an investigational therapy for chronic plaque psoriasis (CPP). This randomized, global, double-blind, vehicle-controlled, dose-ranging trial aims to evaluate the efficacy and safety of ZL-1102 as a topical treatment.
In March 2024, Alumis Inc. announced the presentation of promising clinical data from a Phase II trial of ESK-001, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, for treating patients with moderate-to-severe plaque psoriasis. These findings were shared during a late-breaking session at the American Academy of Dermatology (AAD) Annual Meeting, taking place from March 8-12 in San Diego, California.
In February 2024, Biocon Biologics announced that it has entered into a settlement and license agreement with Janssen Biotech Inc. and Johnson & Johnson (collectively referred to as Janssen), paving the way for the commercialization of its Bmab 1200, a proposed biosimilar to Stelara, in the United States.

Psoriasis Overview

Psoriasis is a chronic autoimmune skin condition that causes the rapid buildup of skin cells, leading to thick, red patches covered with silvery scales. It commonly appears on the scalp, elbows, knees, and lower back but can affect any area of the body. Psoriasis can be triggered by factors like stress, infections, or injuries to the skin, and it often fluctuates between periods of flare-ups and remission. Although there is no cure, treatments such as topical creams, light therapy, and medications can help manage symptoms and reduce flare-ups.

Get a Free Sample PDF Report to know more about Psoriasis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/psoriasis-pipeline-insight

Emerging Psoriasis Drugs Under Different Phases of Clinical Development Include:

FRTX-03: Fresh Tracks Therapeutics
IMG-008: Inmagene
SFA 002: SFA Therapeutics
PBF-1650: Palobiofarma
SCD-044: Sun Pharmaceutical Industries Limited
Rimegepant: Biohaven Pharmaceuticals, Inc.
PPC-06: Dr. Reddy’s
MP1032: MetrioPharm
CT-P43: Celltrion
ABP 654: Amgen
Piclidenoson: Can-Fite Biopharma

Psoriasis Route of Administration

Psoriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Oral
Parenteral
Intravenous
Subcutaneous
Topical

Psoriasis Molecule Type

Psoriasis Products have been categorized under various Molecule types, such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Psoriasis Pipeline Therapeutics Assessment

Psoriasis Assessment by Product Type
Psoriasis By Stage and Product Type
Psoriasis Assessment by Route of Administration
Psoriasis By Stage and Route of Administration
Psoriasis Assessment by Molecule Type
Psoriasis by Stage and Molecule Type

DelveInsight’s Psoriasis Report covers around 80+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Psoriasis product details are provided in the report. Download the Psoriasis pipeline report to learn more about the emerging Psoriasis therapies

Some of the key companies in the Psoriasis Therapeutics Market include:

Key companies developing therapies for Psoriasis are – AbbVie Inc., Amgen Inc., AstraZenca, Biogen Idec, Boehringer Ingelheim, Celgene Corporation, Dr.Reddy`s Laboratories, Eli Lilly and Company, Forward Pharma, Johnson and Johnson (Janssen Biotech Inc.), Leo Pharma AS, Merck and Co. Inc., Novartis AG, Pfizer Inc., Stiefel Laboratories Inc., Sun pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, UCB SA, Valeant Pharmaceuticals, and others.

Psoriasis Pipeline Analysis:

The Psoriasis pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Psoriasis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Psoriasis Treatment.
Psoriasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Psoriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Psoriasis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Psoriasis drugs and therapies

Psoriasis Pipeline Market Drivers

Increasing prevalence of Psoriasis across the globe, increasing combinational therapies, an increase witnessed in Biological therapy approvals for Psoriasis are some of the important factors that are fueling the Psoriasis Market.

Psoriasis Pipeline Market Barriers

However, side effects associated with the treatment, high-cost treatment and Unfavourable Reimbursement policies and other factors are creating obstacles in the Psoriasis Market growth.

Scope of Psoriasis Pipeline Drug Insight

Coverage: Global
Key Psoriasis Companies: Fresh Tracks Therapeutics, Inmagene, SFA Therapeutics, Palobiofarma, Sun Pharmaceutical Industries Limited, Biohaven Pharmaceuticals, Inc., Dr. Reddy’s, MetrioPharm, Celltrion, Amgen, Can-Fite Biopharma, and others
Key Psoriasis Therapies: FRTX-03, IMG-008, SFA 002, PBF-1650, SCD-044, Rimegepant, PPC-06, MP1032, CT-P43, ABP 654, Piclidenoson, and others
Psoriasis Therapeutic Assessment: Psoriasis current marketed and Psoriasis emerging therapies
Psoriasis Market Dynamics: Psoriasis market drivers and Psoriasis market barriers

Request for Sample PDF Report for Psoriasis Pipeline Assessment and clinical trials

Table of Contents

1. Psoriasis Report Introduction

2. Psoriasis Executive Summary

3. Psoriasis Overview

4. Psoriasis- Analytical Perspective In-depth Commercial Assessment

5. Psoriasis Pipeline Therapeutics

6. Psoriasis Late Stage Products (Phase II/III)

7. Psoriasis Mid Stage Products (Phase II)

8. Psoriasis Early Stage Products (Phase I)

9. Psoriasis Preclinical Stage Products

10. Psoriasis Therapeutics Assessment

11. Psoriasis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Psoriasis Key Companies

14. Psoriasis Key Products

15. Psoriasis Unmet Needs

16 . Psoriasis Market Drivers and Barriers

17. Psoriasis Future Perspectives and Conclusion

18. Psoriasis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Psoriasis Pipeline 2024: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Johnson and Johnson, Janssen Biotech, Leo Pharma, Merck, Novartis, Pfizer, AbbVie Inc

Quinn Avery’s Lost Girls of Kato Weaves Together An Unconventional Love Story with a Harrowing Mystery In A Way That Defies Time and Destiny

A gripping dual-timeline mystery that beautifully weaves together the hopes and dreams of a girl in 1986 and those of a modern-day woman, Lost Girls of Kato by Quinn Avery is a heartbreaking and heartfelt story that delivers suspense, twists, and unforgettable characters in a small town full of secrets.

Quinn Avery is a bestselling author of over 45 captivating titles spanning various genres including romantic suspense, young adult paranormal, psychological thriller, and mystery. Quinn honed her talent for crafting intricate puzzles through her smart and quirky Bexley Squires mystery series. In addition, her contemporary suspense thrillers, often set in her beloved locales such as Mankato and Lake Shetek, are nothing short of addictive, leaving readers spellbound with their mind-spinning twists.

When Quinn and her husband aren’t off on adventures, they split their time between farming near their Minnesota acreage and enjoying the tranquility of their lake home.

This one-on-one interview shares Quinn’s background and experience writing Lost Girls of Kato.

Tell us about Lost Girls of Kato.

In the year 1986, 12-year-old Jackie Tanner leads a desolate existence alongside a flighty older sister and an absent mother. It isn’t until Jackie meets an older boy on the banks of the river that she understands the value of love and the bonds of friendship. But J.R. is only in southern Minnesota because his father, a police detective, is aiding local authorities in the search for missing girls. After the community goes into lockdown to protect their children, Jackie and J.R. navigate through the highs and lows of their complicated lives as close confidants.

In the year 2018, 32-year-old Sterling Pruitt is inexplicably lured from Los Angeles to a small Midwestern city where her lifelong dreams involving a little girl become even more vivid…tangible, even. When Sterling learns of the city’s haunting secrets, she confides in Theo, the handsome yet sullen carpenter hired to renovate her new home. Together, Sterling and Theo will question both their destinies and their grips on reality.

Once Sterling begins to understand the gravity of her dreams, she’ll do everything in her power to unlock the mystery behind the abductions in 1986. But can she bring the lost girls home?

What inspired you to write Lost Girls of Kato?

My goal was to revisit the innocence of my childhood in Mankato, Minnesota in the 1980s by capturing the feel of that time and place.

I wanted to create a moving story that would resonate with readers and stay with them long after they finished it.

How did your background and experience influence your writing?

As a lifelong movie fanatic and avid reader of mysteries and thrillers, my passion for storytelling began early. I’ve known since the third grade that I wanted to create stories to entertain others.

Now, as I approach my 50th published book, I can confidently say that my craft has evolved with experience. This milestone is not just a celebration of my journey but a testament to the enduring power of storytelling to connect us to the past and inspire the future.

What is one message you would like readers to remember?

This enchanting, heartfelt, and often agonizing tale of friendship and tragedy is designed to serve as a poignant reminder that the bonds of true love we share can leave an indelible mark on our hearts, shaping us in ways we never imagined.

But, what if life holds more than we think we know? The book invites readers to explore life’s hidden depths, challenging perceptions and inspiring reflection long after the last page is turned.

Purchasing the Book

Lost Girls of Kato has received positive reviews from well-known literary organizations, authors, and reviewers around the world. IndieReader writes, “LOST GIRLS OF KATO delicately blends a touch of the paranormal with driving romantic suspense…a sad and beautiful page turner.” In addition, BestThrillers.com writes, “A clever psychic thriller steeped in 80s nostalgia that will delight Stranger Things fans and anyone looking for a great read.”

The book is available for sale on Amazon. Readers are encouraged to purchase their copy today: https://www.amazon.com/Lost-Girls-Kato-Quinn-Avery-ebook/dp/B0BSG3KZ3X

To connect with Quinn and learn more about her work and upcoming book releases, visit: https://www.quinnavery.com. You can also find her on Facebook, YouTube, and Instagram.

Media Contact
Company Name: Author News Network
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: authornewsnetwork.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Quinn Avery’s Lost Girls of Kato Weaves Together An Unconventional Love Story with a Harrowing Mystery In A Way That Defies Time and Destiny

Oncolytic Virus Cancer Therapy Pipeline 2024: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | CG Oncology, Targovax, Transgene, Istari Oncology, Targovax, Oncolytics Biotech

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Oncolytic Virus Cancer Therapy pipeline constitutes 120+ key companies continuously working towards developing 125+ Oncolytic Virus Cancer Therapy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Oncolytic Virus Cancer Therapy Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Oncolytic Virus Cancer Therapy Market.

The Oncolytic Virus Cancer Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report:

Companies across the globe are diligently working toward developing novel Oncolytic Virus Cancer Therapy treatment therapies with a considerable amount of success over the years.
Oncolytic Virus Cancer Therapy companies working in the treatment market are DNAtrix, Nouscom, Astellas Pharma, CG Oncology, Targovax, Transgene, Istari Oncology, Targovax, Oncolytics Biotech, and others, are developing therapies for the Oncolytic Virus Cancer Therapy treatment

Emerging Oncolytic Virus Cancer Therapy therapies in the different phases of clinical trials are- DNX 2440, NOUS PEV, ASP 9801, CG0070, ONCOS-102, TG 6002, PVS-RIPO, DNX-2401, ONCOS 102, Pelareorep, CG0070, and others are expected to have a significant impact on the Oncolytic Virus Cancer Therapy market in the coming years.
In November 2024, Mustang Bio, Inc. (Nasdaq: MBIO), a clinical-stage biopharmaceutical company dedicated to advancing cell therapies for challenging cancers, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Mustang for MB-108, a herpes simplex virus type 1 (HSV-1) oncolytic virus, for the treatment of malignant glioma.
In April 2024, Replimune has shared interim findings from ARTACUS, a Phase I/II clinical trial evaluating RP1 monotherapy for skin cancers in patients who have received solid organ or hematopoietic cell transplants. Currently, RP1 is being tested in the Phase II IGNYTE study, a multi-cohort clinical trial that combines RP1 with OPDIVO.
In March 2024, The FDA has granted fast track designation to MVR-T3011, an oncolytic virus product administered via intratumoral injection, for treating patients with recurrent or metastatic HNSCC whose disease has progressed after platinum-based chemotherapy and at least one prior line of anti-PD-1/PD-L1 therapy. MVR-T3011 is a proprietary 3-in-1 oncolytic virus developed by ImmVira. This genetically engineered agent aims to combine the most beneficial features of attenuated HSV-1, including replication potency in tumor cells and limited replication in normal cells. It functions by incorporating a PD-1 antibody and IL-12, which further enhances immune responses within the tumor microenvironment.

Oncolytic Virus Cancer Therapy Overview

Oncolytic virus (OV) cancer therapies are virus-based treatment modalities that infect and kill cancer cells, and by releasing tumor-specific antigens, also serve as an in situ cancer vaccine. Myxoma virus and reovirus are two examples of viruses that naturally target tumour cells while being nonpathogenic to healthy human cells.

Get a Free Sample PDF Report to know more about Oncolytic Virus Cancer Therapy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-pipeline-insight-2021

Emerging Oncolytic Virus Cancer Therapy Drugs Under Different Phases of Clinical Development Include:

DNX 2440: DNAtrix
NOUS PEV: Nouscom
ASP 9801: Astellas Pharma
CG0070: CG Oncology
ONCOS-102: Targovax
TG 6002 : Transgene
PVS-RIPO: Istari Oncology
DNX-2401: DNAtrix
ONCOS 102: Targovax
Pelareorep: Oncolytics Biotech
CG0070: CG Oncolgy

Oncolytic Virus Cancer Therapy Route of Administration

Oncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Intranasal
Intravenous
Oral
Oral/Intravenous
Parenteral
Subcutaneous
Subcutaneous/Intramuscular

Oncolytic Virus Cancer Therapy Molecule Type

Oncolytic Virus Cancer Therapy Products have been categorized under various Molecule types, such as

Oncolytic Viruse

Oncolytic Virus Cancer Therapy Pipeline Therapeutics Assessment

Oncolytic Virus Cancer Therapy Assessment by Product Type
Oncolytic Virus Cancer Therapy By Stage and Product Type
Oncolytic Virus Cancer Therapy Assessment by Route of Administration
Oncolytic Virus Cancer Therapy By Stage and Route of Administration
Oncolytic Virus Cancer Therapy Assessment by Molecule Type
Oncolytic Virus Cancer Therapy by Stage and Molecule Type

DelveInsight’s Oncolytic Virus Cancer Therapy Report covers around 125+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Oncolytic Virus Cancer Therapy product details are provided in the report. Download the Oncolytic Virus Cancer Therapy pipeline report to learn more about the emerging Oncolytic Virus Cancer Therapy therapies

Some of the key companies in the Oncolytic Virus Cancer Therapy Therapeutics Market include:

Key companies developing therapies for Oncolytic Virus Cancer Therapy are – Lokon Pharma, Merck, Wuhan Binhui Biotechnology, CG Oncology, Oncolys Biopharma, Replimune, Transgene, Sorrento Therapeutics, ORCA Therapeutics, TILT Biotherapeutics, BioEclipse Therapeutics, Oncolytics Biotech, Oncorus, DNAtrix, OncoMyx Therapeutics, Vyriad, Boehringer Ingelheim, IconOVir Bio, Imugene, Turnstone Biologics, Immvira Pharma, SillaJen Biotherapeutics, Advantagene, Nouscom, TOT Biopharm, Elicera Therapeutics, Takeda, Candel Therapeutics, Valo Therapeutics, Tessa Therapeutics, PsiOxus Therapeutics, KaliVir Immunotherapeutics, Oncos Therapeutics, Mustang Bio, Takara Bio, Vaxiion Therapeutics, Synthetic Biologics, Calidi Biotherapeutics, Genelux Corporation, Shanghai Sunway Biotech, BioInvent International AB, Guizhou Sinorda Biomedicine, EpicentRx, Hookipa Pharma Inc., Imvaq Therapeutics, Seneca Therapeutics, AmunBio, Orgenesis, Protheragen, Astellas Pharma, and others.

Oncolytic Virus Cancer Therapy Pipeline Analysis:

The Oncolytic Virus Cancer Therapy pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Oncolytic Virus Cancer Therapy with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Oncolytic Virus Cancer Therapy Treatment.
Oncolytic Virus Cancer Therapy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Oncolytic Virus Cancer Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Oncolytic Virus Cancer Therapy market.

Download Sample PDF Report to know more about Oncolytic Virus Cancer Therapy drugs and therapies

Oncolytic Virus Cancer Therapy Pipeline Market Drivers

Increase in the number of patients with cancers, rising need for advanced and effective cancer therapeutics for improved quality of life are some of the important factors that are fueling the Oncolytic Virus Cancer Therapy Market.

Oncolytic Virus Cancer Therapy Pipeline Market Barriers

However, lack of development, scaleup and commercialisation resources available to developers, lack of awareness about the new class of anticancer immunotherapy and other factors are creating obstacles in the Oncolytic Virus Cancer Therapy Market growth.

Scope of Oncolytic Virus Cancer Therapy Pipeline Drug Insight

Coverage: Global
Key Oncolytic Virus Cancer Therapy Companies: DNAtrix, Nouscom, Astellas Pharma, CG Oncology, Targovax, Transgene, Istari Oncology, Targovax, Oncolytics Biotech, and others
Key Oncolytic Virus Cancer Therapy Therapies: DNX 2440, NOUS PEV, ASP 9801, CG0070, ONCOS-102, TG 6002, PVS-RIPO, DNX-2401, ONCOS 102, Pelareorep, CG0070, and others
Oncolytic Virus Cancer Therapy Therapeutic Assessment: Oncolytic Virus Cancer Therapy current marketed and Oncolytic Virus Cancer Therapy emerging therapies
Oncolytic Virus Cancer Therapy Market Dynamics: Oncolytic Virus Cancer Therapy market drivers and Oncolytic Virus Cancer Therapy market barriers

Request for Sample PDF Report for Oncolytic Virus Cancer Therapy Pipeline Assessment and clinical trials

Table of Contents

1. Oncolytic Virus Cancer Therapy Report Introduction

2. Oncolytic Virus Cancer Therapy Executive Summary

3. Oncolytic Virus Cancer Therapy Overview

4. Oncolytic Virus Cancer Therapy- Analytical Perspective In-depth Commercial Assessment

5. Oncolytic Virus Cancer Therapy Pipeline Therapeutics

6. Oncolytic Virus Cancer Therapy Late Stage Products (Phase II/III)

7. Oncolytic Virus Cancer Therapy Mid Stage Products (Phase II)

8. Oncolytic Virus Cancer Therapy Early Stage Products (Phase I)

9. Oncolytic Virus Cancer Therapy Preclinical Stage Products

10. Oncolytic Virus Cancer Therapy Therapeutics Assessment

11. Oncolytic Virus Cancer Therapy Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Oncolytic Virus Cancer Therapy Key Companies

14. Oncolytic Virus Cancer Therapy Key Products

15. Oncolytic Virus Cancer Therapy Unmet Needs

16 . Oncolytic Virus Cancer Therapy Market Drivers and Barriers

17. Oncolytic Virus Cancer Therapy Future Perspectives and Conclusion

18. Oncolytic Virus Cancer Therapy Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Oncolytic Virus Cancer Therapy Pipeline 2024: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | CG Oncology, Targovax, Transgene, Istari Oncology, Targovax, Oncolytics Biotech

Rubic Management Revolutionizes Business Growth With “Systems Made Simple” Approach

Rubic Management, a leader in business automation solutions, is transforming the way entrepreneurs streamline operations and achieve sustainable growth. Guided by its “Systems Made Simple” philosophy, Rubic provides an all-in-one software platform designed to help businesses reclaim lost time, recover missed opportunities, and focus on what matters most—their growth.

Addressing the Challenges Entrepreneurs Face

Running a business comes with its fair share of complexities. According to research from IDC, companies can lose between 20% and 30% of their revenue annually due to inefficient business systems or a lack of proper systems, which translates to a significant impact on their bottom line. These challenges leave entrepreneurs frustrated and overburdened, struggling to balance day-to-day operations with long-term strategic goals.

Recognizing these pain points, Rubic Management—commonly known as Rubic—has developed a comprehensive, user-friendly software platform to simplify business systems. By offering a single hub with all the tools entrepreneurs need, Rubic empowers business owners to take control of their operations with confidence.

“Systems Made Simple”: A Path to Success

At the core of Rubic Management’s offering is its innovative “Systems Made Simple” framework. This framework, partnered with their powerful software platform consolidates fragmented processes, offering entrepreneurs intuitive tools to streamline workflows, nurture leads, and retain customers.

Getting started is simple: every new user is guided through the platform with an easy-to-follow onboarding process. The Rubic Playbook, an interactive feature within the software, evaluates each user’s business and provides a personalized dashboard highlighting key metrics and actionable strategies for growth. With built-in tutorials and step-by-step prompts, the software ensures users can implement these strategies seamlessly and independently.

“Many entrepreneurs are overwhelmed by fragmented systems that fail to communicate effectively,” says Zac Harms, Founder and CEO of Rubic. “Our platform and framework solves this by offering everything they need in one place, providing clarity, efficiency, and, most importantly, time savings.”

Real Stories, Real Impact

The impact of Rubic’s software is best illustrated through the experiences of its users. Eric, a small business owner, shared how Rubic transformed his operations:“Before Rubic, I was managing multiple disconnected tools that left me feeling burnt out. Now, with Rubic’s all-in-one platform, I save 10 hours a week—time I can dedicate to growing my business.”

Kelly, another user, faced similar struggles:“I used to feel like I was constantly spinning my wheels, trying to keep everything running smoothly. Rubic’s tools gave me a clear, manageable system, and I finally feel in control of my business.”

These testimonials underscore the tangible value of Rubic’s software—saving time, reducing stress, and unlocking growth potential.

Innovating for the Future

Rubic’s commitment to innovation extends beyond its current offerings. The company is actively developing a full suite of AI-driven tools that will further enhance the platform. These advanced features aim to automate critical tasks like scheduling, customer behavior analysis, and lead prioritization, allowing users to focus on strategic decision-making while the AI manages day-to-day processes.

“Imagine having an AI assistant that predicts sales trends, schedules meetings, and manages customer interactions,” says Zac Harms. “That’s the future we’re building with Rubic—a future where entrepreneurs can fully focus on growing their businesses.”

A Trusted Partner for Entrepreneurs

Rubic Management’s software solutions are designed specifically for small business owners and entrepreneurs in the United States. The company has earned a reputation for reliability and results, with features in trusted publications like FOX and Benzinga reinforcing its position as a leader in business automation.

“Rubic’s platform isn’t just a tool—it’s a roadmap for success,” says Zac Harms. “We’ve designed it to ensure no opportunity is lost and to give every entrepreneur the resources they need to thrive.”

Take the First Step Today

Entrepreneurs ready to transform their businesses can visit Rubic Management to learn more about the platform’s capabilities. Detailed information about features and pricing options is readily available on the website.

With its focus on simplicity, innovation, and results, Rubic is empowering entrepreneurs to build the businesses they’ve always envisioned. By offering a streamlined software platform that eliminates inefficiencies, Rubic ensures users can lead with confidence and achieve their goals.

Media Contact
Company Name: Rubic Management LLC
Contact Person: Zac Harms
Email: Send Email
Phone: +1 (877) 660-7564
Country: United States
Website: https://rubicmanagement.com

Tech Meets Speech Therapy: Speak For Less’ Modern Solution for Stuttering Challenges

Speak For Less is transforming the lives of people who stutter across the United States with its modern anti-stuttering device, known as the FluencyPods. This modern-day tool has become an essential resource for many to enhance speech fluency, enabling individuals to communicate more confidently and effectively in various speaking scenarios.

FluencyPods

The FluencyPods have garnered adoption, not just among individuals seeking greater fluency, but also within the speech therapy community. Speech and language pathologists (SLPs) and speech therapy centers across the country are introducing the device into their practice to help clients achieve better outcomes. By integrating the FluencyPods into sessions, SLPs can offer clients the opportunity to experience real-time fluency improvements in challenging speaking situations, such as public speaking, interviews, or everyday conversations. While it’s not mandatory to use FluencyPods alongside speech therapy, combining the two may provide even greater benefits.

While the device offers remarkable benefits, Speak For Less is committed to transparency. The company emphasizes that the device is not a cure for stuttering—no such cure exists. Instead, it serves as an effective aid, helping to manage the symptoms of stuttering and boost fluency. This honesty has earned the trust of the stuttering community and professionals alike.

With a success rate of 90%, Speak For Less has changed the way many people approach stuttering. The company stands firmly behind its product, offering a 100% money-back guarantee. To ensure that potential users feel confident in their investment, Speak For Less provides a 14-day free trial. During this period, individuals can test the device in real-life speaking scenarios where they typically struggle, such as phone calls, meetings, or social gatherings.

This risk-free approach has made Speak For Less an accessible and trusted solution for people who stutter. By addressing individual needs and integrating seamlessly into speech therapy practices, the device is empowering users to find their voice, communicate with ease, and lead more fulfilling lives. Speak For Less is not just a device—it’s a step toward fluency and confidence.

Speak For Less Logo

Media Contact
Company Name: Speak For Less
Contact Person: Jamie Pell
Email: Send Email
Phone: +1 888-773-2545
Country: United Kingdom
Website: https://www.speakforless.com/

Shelly Revolutionizes Home Efficiency With Smart Energy-Saving Devices

Every day, a significant amount of energy is wasted. Buildings and appliances consume large amounts of electricity, but some of it is lost due to outdated or inefficient technology. This wasted energy increases the carbon footprint, directly contributing to environmental pollution.

However, there is something that people can use to make their home cost-efficient – Shelly’s smart devices. These devices will save energy, and that way the bills will be lower. Shelly’s smart devices send real-time information about the energy use in homes to smart app. This way, people can identify patterns, peak times, or areas of excessive consumption.

Of course, everyone can use these smart devices not only in house or apartment but also in the office or commercial building. Using Shelly’s smart monitoring and energy-saving devices will lower bills and contribute to reducing global pollution.

How Shelly’s Devices Can Save Energy

Smart devices can monitor and control the energy used by each lamp and appliance. These features allow to switch lights on and off throughout the home and adjust the heating. Shelly’s devices can also detect if any appliance in the system is malfunctioning.

Automated Control Systems

Smart thermostats, controllers, plugs, and relay switches can control the system remotely. That way, these devices can optimize energy use. Smart features can turn off the lights in empty rooms or outside. Using them will allow to turn off the forgotten lights even when people are away from home.

Smart features can also control the heating in the home – by setting up a special schedule, the smart system can decrease the temperature when nobody are at work and therefore raise it when are coming back home.

Energy Monitoring at Home

Integrating a smart system at home enables to monitor energy consumption. Smart devices provide detailed usage reports – the information is collected and analyzed so people can make appropriate decisions. Shelly’s devices provide real-time information on everything happening at home, and they also allow to identify which appliances consume the most energy and detect any issues in the system so everyone can take appropriate action.

Everyone can control these features through Shelly’s app, platforms, or protocols. This allows to schedule when the outdoor lights should turn on and off, set the temperature for optimal comfort, and monitor energy usage at any time. Monitoring will also help to reduce waste of energy. It will make the house or apartment more cost-efficient and save a lot of money.

Shelly produces a variety of smart devices – relay switches, dimmer switches, plugs, smart controllers, and energy meters. They use different technologies like Bluetooth, Wi-Fi, Z-Wave, and LAN. These features might vary in their method of installation and can be incorporated into already-built smart systems.

How Are Shelly’s Devices Working

The smart devices produced by Shelly need to be connected to electricity, the internet, or Bluetooth. That way, everyone will be able to control everything at home when people are at work or on vacation from app.

Commonly, these devices have step-by-step instructions that are simply described so everyone can make the installation. Everyone have to place these features where they’re needed so they can work effectively. Also, they need to be constantly connected to electricity; otherwise, they won’t function.

More About Safety

It was already said that using smart devices for monitoring will increase the safety of the home. Smart systems can indicate if there is a problem with some appliances, and can take action to prevent an eventual incident.

Also, they can switch on the lights when nobody home – that way, it will appear that someone is home. This can prevent theft and unwanted entry. Smart monitoring devices can also be connected to security cameras, smart locks, gates, and doors. That way, everyone can feel comfortable at home, and won’t worry when they are away.

Why Is the Use of Smart Devices So Important?

Of course, lowering bills and making homes more efficient is great, but the picture is much bigger. Using a smart system at home is related to reducing greenhouse gas emissions. This is something that really matters – it’s related to water and air pollution, which, on the other hand, is linked to climate change. All of these can reflect lifestyle and, most importantly, the health.

Smart homes are the way that will lead to a cleaner environment. If start to integrate smart systems into homes, offices, and commercial buildings, can guarantee a better future for kids. Energy waste is a big problem, and people need to be aware of its consequences.

Media Contact
Company Name: Shelly
Email: Send Email
Country: Germany
Website: https://www.shelly.com/

Radiation Dermatitis Pipeline 2024: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Adamis Pharmaceuticals, Matrix Biomed, BioMimetix JV

Radiation Dermatitis pipeline constitutes key companies continuously working towards developing Radiation Dermatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Radiation Dermatitis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Radiation Dermatitis Market.

The Radiation Dermatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Radiation Dermatitis Pipeline Report:

Companies across the globe are diligently working toward developing novel Radiation Dermatitis treatment therapies with a considerable amount of success over the years. Radiation Dermatitis Key players such as – Adamis Pharmaceuticals, Matrix Biomed, BioMimetix JV, and others, are developing therapies for the Radiation Dermatitis treatment

Radiation Dermatitis Emerging therapies such as – Tempol (APC-400), BMX-001, and others are expected to have a significant impact on the Radiation Dermatitis market in the coming years.
In August 2024, Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on developing novel neuroplastogens for treating neuropsychiatric disorders, and Aries Science & Technology, a developer of encapsulation technologies, announced that Patent No. 12,059,393 was granted in August 2024 to Enveric’s wholly-owned subsidiary, Akos Biosciences, Inc. Enveric also revealed that it has entered into a Licensing Agreement with Aries and Akos for the clinical development of Enveric’s newly-patented topical product for radiation dermatitis and other conditions.

Radiation Dermatitis Overview

Radiation dermatitis is a skin condition caused by exposure to radiation, commonly occurring in patients undergoing radiation therapy for cancer treatment. It typically presents as redness, dryness, itching, or peeling of the skin, and in more severe cases, it can lead to blistering or ulceration. The severity of radiation dermatitis varies depending on factors such as the dose of radiation, the area treated, and individual skin sensitivity. Treatment focuses on managing symptoms and preventing further skin damage through moisturizing creams, ointments, and avoiding irritants.

Get a Free Sample PDF Report to know more about Radiation Dermatitis Pipeline Assessment-

https://www.delveinsight.com/report-store/radiation-dermatitis-pipeline-insight

Emerging Radiation Dermatitis Drugs Under Different Phases of Clinical Development Include:

Tempol (APC-400): Adamis Pharmaceuticals/ Matrix Biomed
BMX-001: BioMimetix JV

Radiation Dermatitis Pipeline Therapeutics Assessment

Radiation Dermatitis Assessment by Product Type
Radiation Dermatitis By Stage and Product Type
Radiation Dermatitis Assessment by Route of Administration
Radiation Dermatitis By Stage and Route of Administration
Radiation Dermatitis Assessment by Molecule Type
Radiation Dermatitis by Stage and Molecule Type

DelveInsight’s Radiation Dermatitis Report covers around products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Download Sample PDF Report to know more about Radiation Dermatitis drugs and therapies

Radiation Dermatitis Pipeline Analysis:

The Radiation Dermatitis pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the Radiation Dermatitis treatment with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Radiation Dermatitis Treatment.
Radiation Dermatitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Radiation Dermatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Radiation Dermatitis market.

Further Radiation Dermatitis product details are provided in the report. Download the Radiation Dermatitis pipeline report to learn more about the emerging Radiation Dermatitis therapies

Radiation Dermatitis Pipeline Market Drivers

Radiation therapy (RT) is a frequently used modality for cancer treatment. As a result, a huge population suffers from RD, which presents a huge market to any new entrant.
The diagnosis of the disorder is easy with a clear clinical presentation, which helps in identifying the disease.

Radiation Dermatitis Pipeline Market Unmet Needs

Challenges in diagnosis
Development of novel therapies
Limitations in gene therapy
Poor disease understanding
Clinical biomarkers

Scope of Radiation Dermatitis Pipeline Drug Insight

Coverage: Global
Key Radiation Dermatitis Companies: Adamis Pharmaceuticals, Matrix Biomed, BioMimetix JV, and others
Key Radiation Dermatitis Therapies: Tempol (APC-400), BMX-001, and others
Radiation Dermatitis Therapeutic Assessment: Radiation Dermatitis current marketed and Radiation Dermatitis emerging therapies
Radiation Dermatitis Market Dynamics: Radiation Dermatitis market drivers and Radiation Dermatitis market barriers

Request for Sample PDF Report for Radiation Dermatitis Pipeline Assessment and clinical trials

Table of Contents

1	Radiation Dermatitis Report Introduction
2	Radiation Dermatitis Executive Summary
3	Radiation Dermatitis Overview
4	Radiation Dermatitis- Analytical Perspective In-depth Commercial Assessment
5	Radiation Dermatitis Pipeline Therapeutics
6	Radiation Dermatitis Late Stage Products (Phase II/III)
7	Radiation Dermatitis Mid Stage Products (Phase II)
8	Radiation Dermatitis Early Stage Products (Phase I)
9	Radiation Dermatitis Preclinical Stage Products
10	Radiation Dermatitis Therapeutics Assessment
11	Radiation Dermatitis Inactive Products
12	Company-University Collaborations (Licensing/Partnering) Analysis
13	Radiation Dermatitis Key Companies
14	Radiation Dermatitis Key Products
15	Radiation Dermatitis Unmet Needs
16	Radiation Dermatitis Market Drivers and Barriers
17	Radiation Dermatitis Future Perspectives and Conclusion
18	Radiation Dermatitis Analyst Views
19	Appendix
20	About DelveInsight

About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Radiation Dermatitis Pipeline 2024: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Adamis Pharmaceuticals, Matrix Biomed, BioMimetix JV

JJ Enterprises Expands Digital Marketing Services To Boost Client Success

JJ Enterprises, a leading social media marketing agency, announces the expansion of its services to include cutting-edge strategies tailored for small businesses, empowering them to achieve unparalleled growth in today’s competitive digital landscape.

JJ Enterprises, an innovative social media marketing agency, is proud to announce the launch of its expanded suite of digital marketing services. Designed to cater to the unique needs of small businesses, these enhancements reflect JJ Enterprises’ commitment to delivering measurable results and empowering clients to thrive in the digital era.

The newly introduced services include advanced social media management, targeted ad campaign creation, analytics-driven performance tracking, and bespoke content strategies. With a focus on maximizing return on investment (ROI), JJ Enterprises leverages cutting-edge technology and industry expertise to help businesses build brand visibility and engage with their audiences effectively.

“Our mission has always been to provide personalized, results-driven marketing solutions,” said Jayden James, Founder and CEO of JJ Enterprises. “By expanding our offerings, we’re equipping small businesses with the tools they need to navigate the ever-evolving digital landscape and achieve sustainable growth.”

The expansion comes at a time when small businesses face mounting challenges in maintaining a competitive edge online. JJ Enterprises’ tailored approach ensures that clients receive strategies aligned with their unique goals and target audiences.

Key Features of the Expanded Services:

– Comprehensive Social Media Management: Tailored plans to optimize presence on platforms like Instagram, Facebook, and LinkedIn.

– Targeted Ad Campaigns: Data-driven advertising strategies to maximize audience reach and engagement.

– Performance Analytics: Real-time tracking and detailed reporting to measure campaign success.

– Custom Content Creation: High-quality, engaging content to boost brand identity and audience interaction.

To learn more about JJ Enterprises’ services or to schedule a consultation, visit [https://jj-enterprises.co/booked-8754](https://jj-enterprises.co/booked-8754).

About JJ Enterprises:

JJ Enterprises is a forward-thinking social media marketing agency dedicated to helping small businesses achieve their goals through innovative and customized digital marketing strategies. With a track record of delivering exceptional results, JJ Enterprises remains a trusted partner for businesses seeking to enhance their online presence and drive growth.

For additional inquiries, please contact JJ Enterprises directly at the provided email or phone number.

Media Contact
Company Name: JJ Enterprises
Contact Person: Jayden James
Email: Send Email
Phone: 253-347-6462
Country: United States
Website: https://jj-enterprises.co/booked-8754

Home For Sale In Cleveland GA: Elevating the Home Selling and Buying Experience with Leading Edge Customer Service

Leading Edge Real Estate revolutionizes home-buying in Cleveland, GA, with comprehensive services, including property search, financing assistance, and seamless documentation for stress-free transactions.

Nestled in the foothills of the Appalachian Mountains, Cleveland offers a blend of small-town charm and modern amenities, featuring scenic landscapes, a close-knit community, and a strong local economy that makes it an ideal place to call home. With Leading Edge Real Estate, a trusted name in the region’s real estate market, finding the perfect “home for sale in Cleveland GA” has never been more convenient.

Leading Edge Real Estate provides access to properties in some of the most desirable neighborhoods. From spacious single-family homes to quaint cottages, the company’s listings showcase the diversity of housing options available in the area.

With a dedicated team of experienced professionals, Leading Edge Real Estate sets itself apart by providing end-to-end support for clients navigating the complexities of real estate transactions. From helping clients search for their ideal home to securing financing and handling essential paperwork, the company ensures a seamless experience. This comprehensive approach has earned the company a reputation as a one-stop solution for real estate needs in Cleveland, GA.

Leading Edge Real Estate is known for its client-focused approach, offering services that cater to every step of the home-buying process. The company’s expertise extends beyond traditional property listings, leveraging an extensive database to match buyers with properties that meet their specific needs, preferences, and budgets.

The agency’s user-friendly website, leadingedgega.com, enhances the home-buying experience by providing easy access to property listings, market insights, and helpful resources. Clients can browse available homes, schedule viewings, and connect with agents directly through the platform.

“We are experts in simplifying real estate transactions. At Leading Edge Real Estate, we guarantee and deliver professional, courteous, and dependable service. Whether you’re simply buying or selling your first home or investing in your dream property, our years of experience and dedication to excellent service ensure we will exceed your expectations,” said James Allison, the owner-operator of Leading Edge Real Estate.

What distinguishes Leading Edge Real Estate is its commitment to personalized and transparent service, ensuring its clients’ unique requirements are met. Understanding the financial challenges of purchasing a home, Leading Edge Real Estate collaborates with reputable lenders to provide attractive loan options, ensuring buyers secure competitive rates. Handling the complex documentation required for real estate transactions, the team streamlines the process, saving clients valuable time and reducing stress.

For more information, visit https://leadingedgega.com/

For homeowners looking to sell property, Leading Edge’s expert real estate agents stand ready to assist with a personalized approach to maximize their property’s value. Allison and his team offer unmatched customer service and many resources to simplify the selling process. A proven leader in real estate strategies, its successful property listings have not exceeded 30 days over the last eight years.

Extensive experience and knowledge of the Cleveland real estate market allow Leading Edge to identify prime opportunities for buyers and sellers. Whether searching for a starter home, upgrading to a larger space, or exploring investment properties, the agency has the expertise to deliver results.

With knowledgeable agents committed to helping sell and buy homes quickly at the best price, Leading Edge Real Estate is known for its integrity, professionalism, and a deep commitment to customer satisfaction. By simplifying the real estate journey and offering unparalleled support, the company emerges as a trusted partner for buyers and sellers in Cleveland, GA.

About the Company:

Based in Cleveland, GA, Leading Edge Real Estate offers end-to-end services for buyers and sellers, ensuring a streamlined process and stress-free experience. Committed to transparency and personalized service, Leading Edge Real Estate caters to diverse client needs, leveraging its extensive market knowledge and a user-friendly platform to connect clients with their dream homes. Dedicated to excellence, it remains a trusted partner in the thriving Cleaveland real estate market.

Media Contact
Company Name: Leading Edge Real Estate
Contact Person: James Allison
Email: Send Email
Phone: (706) 200-2210
Address:538 E Kytle Street
City: Cleveland
State: GA 30528
Country: United States
Website: https://leadingedgega.com/

Discover Edgewater, FL: Nature, Adventure, and Small-Town Charm

Established in 1851 as Hawks Park, named after its founder, Dr. John Milton Hawk, the intercoastal city of Edgewater is today a thriving community that still retains its small-town charm. Once home to citrus growers and beekeepers—in fact, in 1888, 11 tons of local honey were shipped via steamboat from here—Edgewater is now a prime destination for those looking to explore the area’s blueways. With its proximity to the Indian River and Mosquito Lagoon, the city offers an incredible diversity of wildlife and countless ways to enjoy the scenic environment: over 150 acres of parks, a beautiful riverside recreation path, paddling trails, and public boat launches.

Where to Stay in Edgewater, FL

Check into the centrally located Best Western Edgewater for a stay perfect for families, a romantic weekend, or a friends’ getaway. The cozy, clean, and well-appointed rooms feature all the modern conveniences, and boaters will appreciate the spacious parking lot.

Must-Try Restaurants and Local Gems

Visitors will find a variety of dining options in Edgewater, from cozy taverns to family-friendly fare to menus covering the world’s diversity. Family-owned JC’s Riptides serves up fine steak and seafood, specializing in broiled rock shrimp and slow-roasted prime rib. For some live music to accompany a meal or to shoot pool after a dinner of pub grub, go to Tailgatorz.

Fancy a cuppa? Sample some locally grown tea at Rise Yaupon. The team leads tours of the facility and educates guests about the Yaupon holly, a Florida species found abundantly here. The Dutch Oven Bread Co. is located next door, with a selection of breads and pastries to enjoy with the tea.

Explore Edgewater’s Natural Wonders

Edgewater is home to an array of birds, fish, dolphins, manatees, and other unique marine and terrestrial species, making it a haven for nature enthusiasts and wildlife photographers.

Many visitors come to the area to explore the water via several boat ramps in town. Menard-May Park, along the Indian River, features playgrounds, volleyball courts, picnic tables, a fishing pier, and kayak and boat launches. George R. Kennedy Memorial Park, across from City Hall, has four boat ramps and a fishing pier with a gazebo.

For those wanting to celebrate a special event, spend an afternoon boating and swimming, or take in a glorious sunset before or after dinner, Toon Tikni Charters has several cruises, lasting from 90 minutes to three hours. Private cruises are also available.

Edgewater is the perfect blend of peaceful vibes, natural beauty, and crystal-blue waters, offering something fun and memorable for visitors of all ages.

For more information:

Please visit VisitNSBfl.com or call 386-428-1600.

Follow Facebook.com/VisitNewSmyrnaBeach or @visitnewsmyrnabeach on Instagram for the latest news.

Media Contact
Company Name: Visit New Smyrna Beach Area
Contact Person: Aline Gill
Email: Send Email
Country: United States
Website: https://insider.visitnsbfl.com/